In this view, the activation of TLR3 on the membrane of cancer cells could act as a trigger for the immune response against cancer (Fig. 1) and, by inducing both tumour cell death and anticancer immune stimulation, could synergize for optimal immunochemotherapy in PCa. The gene discussed is TLR3; the disease is posterior cortical atrophy.